1. Pink Sheet

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

 
• By Cathy Kelly

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

There is Not Much Else To Like In The 340B ADR Rule For Pharma. • Source: Shutterstock

Manufacturers can pursue claims against 340B hospitals and other providers when they provide rebates in the Medicaid managed care program for drugs already purchased at a 340B discount, the Health Resources and Services Administration stated in its final rule on the 340B administrative dispute resolution (ADR) process.

Key Takeaways

  • Manufacturers may have a win in the 340B administrative dispute resolution final rule in that HRSA appears to side with their arguments that providers should be responsible for rectifying duplicate discounts in the Medicaid managed care program

The ADR process is meant to help rectify disputes between manufacturers and 340B-eligible hospitals and other providers related to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 
• By Neena Brizmohun

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.